Healthcare / BiotechnologyLSE
$0.24
+0.01 (+4.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-1.9M · FCF $-2.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $396000.00 | $442000.00 | — |
| Net Income | $-1.9M | $-1.9M | $-3.1M | $-4.0M | $-2.7M |
| EBITDA | $-2.0M | $-2.0M | $-3.5M | $-5.1M | $-3.2M |
| EPS | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Operating Margin | — | — | -899.0% | -1147.1% | — |
| Net Margin | — | — | -792.2% | -914.7% | — |
| Balance Sheet | |||||
| Current Ratio | 2.29 | 2.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.4M | $-2.4M | $-3.0M | $-4.1M | $-2.6M |
| Returns | |||||
| ROE | -32.5% | -32.5% | -134.0% | -75.7% | -29.6% |
| Valuation | |||||
| P/B | 22.53 | 22.53 | 93.94 | 187.86 | 111.72 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -10.4% | — | — |
| EPS Growth | 68.4% | 68.4% | 22.4% | -48.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.00
Residual
-12.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.